Study suggests mCRC patients who take Bevacizumab beyond progresssion have significantly increased s

I just read an article in press for Clinical Colorectal Cancer

Survival Outcomes of Bevacizumab Beyond
Progression in Metastatic Colorectal Cancer
Patients Treated in US Community Oncology - T. Cartwright

it indicates that mCRC patients who have completed their first line therapy and then take Bevacizumab (Avastin) during second line treatment (beyond progression) have a 6 month advantage in overall survival versus those that did not take Bevacizumab


this is consistent with information published in 2008 by Dr. Grothey